Last reviewed · How we verify
ravidasvir and sofosbuvir — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
ravidasvir and sofosbuvir (ravidasvir and sofosbuvir) — Ascletis Pharmaceuticals Co., Ltd..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| ravidasvir and sofosbuvir TARGET | ravidasvir and sofosbuvir | Ascletis Pharmaceuticals Co., Ltd. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- ravidasvir and sofosbuvir CI watch — RSS
- ravidasvir and sofosbuvir CI watch — Atom
- ravidasvir and sofosbuvir CI watch — JSON
- ravidasvir and sofosbuvir alone — RSS
Cite this brief
Drug Landscape (2026). ravidasvir and sofosbuvir — Competitive Intelligence Brief. https://druglandscape.com/ci/ravidasvir-and-sofosbuvir. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing